# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
- SEC Filing
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates PolyPid (NASDAQ:PYPD) with a Buy and maintains $14 price target.
PolyPid (NASDAQ:PYPD) reported quarterly losses of $(1.25) per share which missed the analyst consensus estimate of $(1.18) by ...
Funding Extends Company's Cash Runway into Second Quarter 2025, which is beyond the Anticipated Timing for SHIELD II Top-...
-SEC Filing
After a Reduction in Surgical Site Infection (SSI) Rates During COVID, Rates are Now Increasing, Signaling a Return to Pre-CO...
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates PolyPid (NASDAQ:PYPD) with a Buy and maintains $14 price target.
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates PolyPid (NASDAQ:PYPD) with a Buy and maintains $14 price target.